Dataset Information

Clinical Evaluation of the CrossNN DNA Methylation Classifier for Central Nervous System Tumors

ABSTRACT: Background: DNA methylation profiling has become an integral diagnostic tool in the classification of central nervous system (CNS) tumors. While the Heidelberg CNS Tumor Methylation Classifier is widely adopted in clinical practice, new classifiers such as CrossNN are emerging. However, the clinical interpretation and added value of these tools within current practices are insufficiently explored. In this study, we evaluated the performance of the CrossNN classifier in a real-world CNS tumor cohort and compared it with the established Heidelberg classifier to assess its potential as both a non-inferior alternative and a complementary tool to improve diagnostic accuracy. Methods: A retrospective cohort of CNS tumors profiled using Illumina Human Methylation 930k EPIC v2 BeadChip arrays was used to evaluate the performance of the CrossNN classifier. Classifier outputs were compared with integrated WHO CNS5 (2021) diagnoses. In addition, CrossNN and Heidelberg outputs were harmonized to WHO CNS5 (2021) tumor entity levels and evaluated both sequentially and in parallel to evaluate their complementarity. Results: A total of 205 samples were included. CrossNN generated correct and confident predictions in 76.1% and showed concordant results with the Heidelberg classifier in 87.3% of cases. Complementary use of both classifiers improved diagnostic accuracy by approximately 10%. Conclusions: CrossNN demonstrated classification performance non-inferior to the Heidelberg classifier, consistent with previously reported CrossNN accuracy. CrossNN therefore represents a robust, alternative methylation-based classifier for CNS tumor classification. Combined use of CrossNN and Heidelberg further improved diagnostic accuracy while retaining a low rate of incorrect predictions.

ORGANISM(S): Homo sapiens

PROVIDER: GSE325845 | GEO | 2026/09/08

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Endometriosis, an estrogen-dependent, progesterone-resistant, inflammatory disorder affects 10% of reproductive-age women. It is diagnosed and staged at surgery, resulting in an 11-year latency from symptom onset to diagnosis, underscoring the need for less invasive, less expensive approaches. Since the uterine lining (endometrium) in women with endometriosis has altered molecular profiles, we tested whether molecular classification of this tissue can distinguish and stage disease. We developed classifiers using genomic data from n=148 archived endometrial samples from women with endometriosis or without endometriosis (normal controls or with other common uterine/pelvic pathologies) across the menstrual cycle and evaluated their performance on independent sample sets. Classifiers were trained separately on samples in specific hormonal milieu, using margin tree classification, and accuracies were scored on independent validation samples. Classification of samples from women with endometriosis or no endometriosis involved two binary decisions each based on expression of specific genes. These first distinguished presence or absence of uterine/pelvic pathology and then no endometriosis from endometriosis, with the latter further classified according to severity (minimal/mild or moderate/severe). Best performing classifiers identified endometriosis with 90-100% accuracy, were cycle phase-specific or independent, and utilized relatively few genes to determine disease and severity. Differential gene expression and pathway analyses revealed immune activation, altered steroid and thyroid hormone signaling/metabolism and growth factor signaling in endometrium of women with endometriosis. Similar findings were observed with other disorders versus controls. Thus, classifier analysis of genomic data from endometrium can detect and stage pelvic endometriosis with high accuracy, dependent or independent of hormonal milieu. We propose that limited classifier candidate-genes are of high value in developing diagnostics and identifying therapeutic targets. Discovery of endometrial molecular differences in the presence of endometriosis and other uterine/pelvic pathologies raises the broader biological question of their impact on the steroid hormone response and normal functions of this tissue. We analyzed endometrial samples from n=148 women without or with endometriosis and/or other uterine/pelvic pathologies, using whole genome microarrays.

Dataset Information

Clinical Evaluation of the CrossNN DNA Methylation Classifier for Central Nervous System Tumors

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets